RYTM Rhythm Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RYTM

Price (delayed)

$43.76

Market cap

$2.63B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.2

Enterprise value

$2.57B

Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within ...

Highlights
The debt has declined by 35% year-on-year and by 13% since the previous quarter
RYTM's revenue is up by 25% QoQ
The quick ratio has declined by 38% year-on-year and by 16% since the previous quarter
Rhythm Pharmaceuticals's equity has decreased by 36% YoY and by 14% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.rhythmtx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of RYTM
Market
Shares outstanding
60.14M
Market cap
$2.63B
Enterprise value
$2.57B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
15.23
Price to sales (P/S)
32.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
33.23
Earnings
Revenue
$77.43M
EBIT
-$170.22M
EBITDA
-$168.46M
Free cash flow
-$136.2M
Per share
EPS
-$3.2
Free cash flow per share
-$2.36
Book value per share
$2.87
Revenue per share
$1.34
TBVPS
$5.65
Balance sheet
Total assets
$332.75M
Total liabilities
$162.99M
Debt
$1.26M
Equity
$169.76M
Working capital
$253.07M
Liquidity
Debt to equity
0.01
Current ratio
5.58
Quick ratio
5.27
Net debt/EBITDA
0.35
Margins
EBITDA margin
-217.6%
Gross margin
88%
Net margin
-238.5%
Operating margin
-238.1%
Efficiency
Return on assets
-55%
Return on equity
-96%
Return on invested capital
-88.4%
Return on capital employed
-61.3%
Return on sales
-219.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RYTM stock price

How has the Rhythm Pharmaceuticals stock price performed over time
Intraday
6.78%
1 week
14.32%
1 month
7.02%
1 year
136.29%
YTD
-4.81%
QTD
0.99%

Financial performance

How have Rhythm Pharmaceuticals's revenue and profit performed over time
Revenue
$77.43M
Gross profit
$68.13M
Operating income
-$184.36M
Net income
-$184.68M
Gross margin
88%
Net margin
-238.5%
The net margin has surged by 69% year-on-year and by 20% since the previous quarter
The operating margin has soared by 69% YoY and by 20% from the previous quarter
RYTM's revenue is up by 25% QoQ
The gross profit has increased by 24% from the previous quarter

Growth

What is Rhythm Pharmaceuticals's growth rate over time

Valuation

What is Rhythm Pharmaceuticals stock price valuation
P/E
N/A
P/B
15.23
P/S
32.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
33.23
The EPS has grown by 8% YoY
RYTM's P/B is 88% above its last 4 quarters average of 8.1
Rhythm Pharmaceuticals's equity has decreased by 36% YoY and by 14% from the previous quarter
RYTM's revenue is up by 25% QoQ
RYTM's price to sales (P/S) is 22% higher than its last 4 quarters average of 26.8

Efficiency

How efficient is Rhythm Pharmaceuticals business performance
The ROS has soared by 70% YoY and by 21% from the previous quarter
The ROE has contracted by 29% YoY and by 12% from the previous quarter
Rhythm Pharmaceuticals's return on invested capital has increased by 20% YoY
The ROA has contracted by 3.2% from the previous quarter

Dividends

What is RYTM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RYTM.

Financial health

How did Rhythm Pharmaceuticals financials performed over time
The total assets is 104% more than the total liabilities
The total liabilities has grown by 38% YoY and by 4% from the previous quarter
The quick ratio has declined by 38% year-on-year and by 16% since the previous quarter
The debt is 99% smaller than the equity
Rhythm Pharmaceuticals's equity has decreased by 36% YoY and by 14% from the previous quarter
The debt has declined by 35% year-on-year and by 13% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.